They ask for more control over diabetic devices

Experts demand improvements in the regulation of usual patients and present medications that regulate blood glucose levels.In addition, new studies denies that insulin is related to the appearance of tumors

The European Association for the Study of Diabetes (EASD) has shown concern about the recent "scandals", in their own words, in which some of the devices used by diabetic patients have been involved, as presented by its president, its president, its president, its president, has presented its president, its president,Andrew Baulton.

These incidents have put to the directives of the European Union that regulate this type of devices in the Center for Care, according to the EASD, also other European medical associations that have repeatedly made calls so that the regulation in the commercialization of this type of devices isimprove.In fact, the European Commission spoke on this last September 26, however for the European Diabetic Organization, it has not sufficiently collected the concern between experts.For the EASD, medical devices are charging an every more important role.Both blood glucose monitors and insulin pumps have become key products.The same subcutaneous sensors.

insulin and cancer
Insulin was precisely a strong point, because an end has put an end to a debate raised this year: the relationship between insulin and cancer.

And this has been in charge of Professor Lucien Abenhaim, from France, who presented the results of the "ISICA" study.At work, women with diabetes and breast cancer were analyzed.Insulin Glargina had no adverse impacts on the history of the existing tumor.Hertzel Gerstein, from Canada, presented another study published in the "New England Journal of Medicine" in which there is no evidence of a possible increased risk of developing cancer between patients treated with glargine.

With regard to pharmacological therapy, the MSD pharmaceutical company presented data from the Phase Iib clinical trial of the MK-3102, a weekly administration drug.Of 685 patients who were studied, 571 received MK-3102 and 114 they took placebo for 12 weeks.The MK-3102 significantly reduced the level of blood glucose.

In Congress there was also space for rare ailments, such as the so -called "death syndrome in bed."A risk of sudden death suffering from type 1 youth diabetics.As explained by Simon Heller, from the University of Sheffield, from the United Kingdom "there are fixative ones that involve night hypoglycemia," says Heller.

However, the issue that most worries experts is linked to the heart.Because, as stressed, it has been shown that the interval called QT (the part of the electrical cycle of the heart) can be altered and extended during an episode of hypoglycemia."Most sudden deaths in young diabetic patients still have no exlpication, but we believe they were due to those arrhythmias," Heller explained.This research line opens a path to prevent fatal episodes of those individuals who use implantable defibrillators.